Key terms
About ALEC
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALEC news
Mar 21
4:12pm ET
Alector Inc Announces Board Retirement and New Members
Mar 07
12:06am ET
Alector’s Clinical Progress and Financial Health Anchor Buy Recommendation
Feb 29
6:40am ET
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC)
Feb 28
7:38am ET
Optimistic Buy Rating for Alector’s AL002 Based on Promising Alzheimer’s Disease Trial Biomarkers and TREM2 Signaling Efficacy
Feb 28
5:37am ET
Alector: Cautious Hold Rating Ahead of Key Clinical Trial Milestones and Financial Assessment
Feb 28
3:37am ET
Alector (ALEC) Receives a Buy from Barclays
Feb 27
7:05pm ET
TD Cowen Sticks to Their Buy Rating for Alector (ALEC)
Feb 27
4:27pm ET
Alector reports Q4 EPS (49c), consensus (77c)
Feb 13
5:27am ET
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Alector (ALEC) and Cytokinetics (CYTK)
Feb 13
5:23am ET
Alector’s Promising Pipeline and Market Potential Affirm Buy Rating
Feb 08
8:01pm ET
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Viking Therapeutics (VKTX) and Zimmer Biomet Holdings (ZBH)
Feb 08
7:12am ET
Alector announces first patient dosed in PROGRESS-AD Phase 2 trial
Feb 07
7:08am ET
Alector, GSK announce FDA granted BTD to latozinemab
Jan 20
3:00am ET
Alector Inc Announces $75 Million Stock Offering Deal
Jan 17
9:10am ET
Alector $75M Spot Secondary priced at $6.90
Jan 17
8:58am ET
Alector announces pricing of $75M public offering of common stock
Jan 16
4:01pm ET
Alector announces common stock offering, no amount given
Jan 07
5:27am ET
Alector (ALEC) Gets a Buy from BTIG
Jan 02
9:09am ET
Alector (ALEC) Gets a Buy from BTIG
Dec 31
5:07am ET
Alector (ALEC) Gets a Buy from BTIG
No recent news articles are available for ALEC
No recent press releases are available for ALEC
ALEC Financials
Key terms
Ad Feedback
ALEC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALEC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
